Proactive Investors - Run By Investors For Investors

ValiRx given US patent boost for its lead therapeutic compound

VAL201 is currently in a Phase I/II study that is assessing safety and tolerability and its effect in the treatment of prostate cancer and other solid tumours
Prostate Cancer UK
So far, VAL201 has met and exceeds the predicted safety and tolerability criteria set for the trial

ValiRx PLC (LON:VAL) saw its shares tick higher on news it has received positive news regarding the US patent application for its lead therapeutic compound, VAL201.

The United States of America patent and trademark office has given notice of allowance for the US Patent Application No.14/575065, otherwise known by the snappy title “Anti-Androgen Peptides and Uses Thereof in Cancer Therapy".

READ: ValiRx given the green light to accelerate progress of prostate cancer drug after encouraging early results

VAL201 is currently in a Phase I/II study that is assessing safety and tolerability and its effect in the treatment of prostate cancer and other solid tumours.

The patent application covers the molecule and use of compounds in pharmaceutically acceptable products. The patent coverage also includes a wide variety of derivatives, modifications and analogues of the compounds and their mode of action; furthermore, the protection sought includes therapeutic formulations with associated delivery systems.

ValiRx said allowance of this US patent will represent one of the cornerstones of its commercial strategy, as ValiRx has already secured patent protection in several other territories, including Europe.

"It is timely and very exciting to receive this notification of allowance for the VAL201 patent,” said Satu Vainikka, the chief executive officer of ValiRx, who noted that the approval comes only weeks after the company received approval from the UK Medicines and Healthcare Products Regulatory Agency and Research Ethics Committee for the company to expand its VAL201.

READ: ValiRx awarded fifth US patent for VAL401 cancer drug

“This US allowance means we can proceed to strengthen the VAL201 patent portfolio and, once granted, will provide ValiRx with patent protection in all its largest commercial markets globally. ValiRx looks forward optimistically to its future prospects," he added.

In afternoon trading, ValiRX shares were 0.5%, or 0.02p higher at 4.88p, having eased back from a session peak of 6.10p.

 -- Adds share price --

View full VAL profile View Profile

ValiRx Plc Timeline

Related Articles

Zelda's Stewart Washer at Proactive's CEO Sessions
November 17 2017
Stewart Washer at Proactive's CEO Sessions this week.
August 17 2017
E-Therapeutics’ network-driven drug discovery platform looks at the broader interactions within disease mechanisms
couple in bed
March 14 2018
MED2002 is a rapid onset gel designed for those men where the current pill-based treatments aren’t appropriate, or carry significant side-effects

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use